Sakuraba, Akihito
Nemoto, Nobuki
Hibi, Noritaka
Ozaki, Ryo
Tokunaga, Sotaro
Kikuchi, Oki
Minowa, Shintaro
Mitsui, Tatsuya
Miura, Miki
Saito, Daisuke
Hayashida, Mari
Miyoshi, Jun
Matsuura, Minoru
Yoneyama, Masayoshi
Ohnishi, Hiroaki
Hisamatsu, Tadakazu
Article History
Received: 14 November 2020
Accepted: 23 April 2021
First Online: 1 May 2021
Declarations
:
: This study was conducted in accordance with the guidelines of the Declaration of Helsinki and with the approval of the Ethics Committee of Kyorin University School of Medicine (Approval Number 806). All patients provided written informed consent.
: Not applicable.
: Tadakazu Hisamatsu (TH) has received grants from Alfresa Pharma Corporation related to the submitted work. TH has received consulting and lecture fees from EA Pharma Co., Ltd.; AbbVie GK.; Celgene K.K.; Janssen Pharmaceutical K.K.; Pfizer Inc.; Takeda Pharmaceutical Co., Ltd.; Mitsubishi Tanabe Pharma Corporation; Kyorin Pharmaceutical Co., Ltd.; JIMRO Co., Ltd.; Mochida Pharmaceutical Co., Ltd.; and Nichi-Iko Pharmaceutical Co., Ltd. outside of the submitted work. TH has also received commercial research funding from EA Pharma Co., Ltd.; AbbVie GK; Daiichi-Sankyo Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Pfizer Inc.; Mochida Pharmaceutical Co., Ltd.; Nippon Kayaku Co., Ltd.; Kyorin Pharmaceutical Co., Ltd.; JIMRO Co.; Mochida Pharmaceutical Co., Ltd.; Astellas Pharma Inc.; Asahi Kasei Medical Co., Ltd.; ZERIA Pharmaceutical Co., Ltd.; and Alfresa Pharma Corporation, outside of the submitted work. Minoru Matsuura (MM) has received consulting and lecture fees from AbbVie GK.; Mitsubishi Tanabe Pharma Corporation.; EA Pharma Co.; Ltd.; Kyorin Pharmaceutical Co., Ltd.; Mochida Pharmaceutical Co., Ltd.; Janssen Pharmaceutical K.K.; Nippon Kayaku Co., Ltd.; and Kissei Pharmaceutical Co., Ltd. outside of the submitted work. MM has also received commercial research funding from AbbVie GK; Mitsubishi Tanabe Pharma Corporation; EA Pharma Co., Ltd.; Mochida Pharmaceutical Co., Ltd.; Nippon Kayaku Co., Ltd.; and JIMRO Co. outside of the submitted work. Hiroaki Ohnishi (HO) has received grants from Alfresa Pharma Corporation related to the submitted work. HO has also received commercial research funding from Ajinomoto Pharmaceutical Co., Ltd. outside of the submitted work. Akihito Sakuraba, Nobuki Nemoto, Noritaka Hibi, Ryo Ozaki, Sotaro Tokunaga, Oki Kikuchi, Shintaro Minowa, Tatsuya Mitsui, Miki Miura, Daisuke Saito, Mari Hayashida, Jun Miyoshi, and Masayoshi Yoneyama have no conflicts of interest.